Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 8/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.45 |
| ▸ | HCAR3 | P49019 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1233899 | 0.88 | HCAR2 (0.64) | HCAR2KMT2ANPSR1L3MBTL1POLB | |
| SCHEMBL21607841 | 0.85 | HCAR2 (0.66) | HCAR2KMT2ANPSR1L3MBTL1POLB | |
| SCHEMBL1259028 | 0.85 | HCAR2 (0.66) | HCAR2KMT2ANPSR1L3MBTL1POLB | |
| SCHEMBL20525148 | 0.85 | KMT2A (0.50) | HCAR2KMT2ANPSR1L3MBTL1POLB | |
| SCHEMBL20468132 | 0.85 | HCAR2 (0.53) | HCAR2KMT2ANPSR1L3MBTL1POLB | |
| SCHEMBL11093186 | 0.85 | KMT2A (0.50) | HCAR2KMT2ANPSR1L3MBTL1POLB | |
| SCHEMBL5724811 | 0.84 | HCAR2 (0.54) | HCAR2KMT2ANPSR1L3MBTL1POLB | |
| SCHEMBL1665229 | 0.84 | DAO (0.58) | HCAR2KMT2ANPSR1L3MBTL1POLB | |
| SCHEMBL17376787 | 0.83 | HCAR2 (0.62) | HCAR2KMT2AL3MBTL1POLBHCAR3 | |
| SCHEMBL14291399 | 0.83 | TP53 (0.50) | HCAR2KMT2ANPSR1L3MBTL1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116284836-A | Metal gel and preparation method thereof | 暨南大学 | 2023-06-23 | — | — | CN | claimed |
| US-20240325409-A1 | Fused Heterotetracyclic Antiviral Agents | ENANTA PHARMACEUTICALS, INC. | 2024-10-03 | — | — | US | disclosed |
| WO-2024182271-A1 | FUSED HETEROTETRACYCLIC ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. (US) | 2024-09-06 | — | — | WO | disclosed |
| WO-2024152995-A1 | MACROCYCLIC CYCLIN INHIBITORS AS WELL AS PREPARATION METHOD THEREFOR AND USE THEREOF | 上海海量医药科技有限公司 | 2024-07-25 | — | — | WO | disclosed |
| EP-3986902-B1 | MACROCYCLIC INHIBITORS OF MCL-1 | JANSSEN PHARMACEUTICA NV (BE) | 2024-01-24 | — | — | EP | disclosed |
| CN-116284836-B | Metal gel and preparation method thereof | 暨南大学 | 2023-07-25 | — | — | CN | disclosed |
| CN-116284836-A | Metal gel and preparation method thereof | 暨南大学 | 2023-06-23 | — | — | CN | disclosed |
| US-10010530-B2 | Carboxamide derivative and its diastereomers in stable crystalline form | Orlon Corporation (FI) | 2018-07-03 | — | — | US | disclosed |
| EP-3016934-B1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME | MILLENNIUM PHARM INC (US) | 2018-01-10 | — | — | EP | disclosed |
| WO-2017182625-A1 | MACROCYCLIC MCL1 INHIBITORS FOR TREATING CANCER | ASTRAZENECA AB (SE) | 2017-10-26 | — | — | WO | disclosed |
| US-20160355504-A1 | HETEROARYL INHIBITORS OF SUMO ACTIVATING ENZYME | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2016-12-08 | — | — | US | disclosed |
| US-20160355504-A1 | HETEROARYL INHIBITORS OF SUMO ACTIVATING ENZYME | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2016-12-08 | — | — | US | disclosed |
| EP-3016934-A2 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME | Millennium Pharmaceuticals, Inc. (US) | 2016-05-11 | — | — | EP | disclosed |
| WO-2015002994-A2 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-01-08 | — | — | WO | disclosed |
| WO-2015002994-A2 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-01-08 | — | — | WO | disclosed |
| EP-1767528-B1 | PROCESS FOR PRODUCING 5-HYDROXY-4-THIOMETHYLPYRAZOLE COMPOUND | IHARA CHEMICAL IND CO (JP) | 2014-09-17 | — | — | EP | disclosed |
| EP-0901488-B1 | 2,4-DIAMINOPYRIMIDINE DERIVATIVES | BASILEA PHARMACEUTICA AG (CH) | 2002-11-06 | — | — | EP | disclosed |
| EP-0901488-A1 | 2,4-DIAMINOPYRIMIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 1999-03-17 | — | — | EP | disclosed |
| US-5866583-A | Substituted 2,4-diaminopyrimidines | HOFFMANN-LA ROCHE INC. (US) | 1999-02-02 | — | — | US | disclosed |
| WO-1997043277-A1 | 2,4-DIAMINOPYRIMIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 1997-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10010530-B2 | Carboxamide derivative and its diastereomers in stable crystalline form | AR, NR5A1, SHBG | HCAR2 92/4885KMT2A 1457/4885NPSR1 206/4885 |
| US-20160355504-A1 | HETEROARYL INHIBITORS OF SUMO ACTIVATING ENZYME | SAE1, SUMO2, SUMO1 | HCAR2 2097/4885KMT2A 888/4885NPSR1 4532/4885 |
| US-20240325409-A1 | Fused Heterotetracyclic Antiviral Agents | HAVCR2, HDGF, SLC10A1 | HCAR2 405/4885KMT2A 4382/4885NPSR1 2507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.